Date: 2015-09-08
Type of information: Series A financing round
Company: ReViral (UK)
Investors: Edmond de Rothschild Investment Partners (France) OrbiMed (USA - NY) Brace Pharma (USA - MD)
Amount: $ 21 million
Funding type:
Planned used: The funding will enable ReViral to progress its lead drug candidate (RV521), which is a highly potent and orally bioavailable potential treatment of RSV infections, into proof of concept clinical trials and to continue the development of a novel series of antiviral inhibitors targeting RSV fusion. RV521 will enter IND enabling toxicology studies in Q4 2015, with the aim of moving into the clinic in 2016.
Others: * On September 8, 2015, ReViral, an antiviral drug discovery and development company, focused on diseases caused by the Respiratory Syncytial Virus (RSV), announced the successful completion of a US $21 million Series A financing. The financing was jointly led by Edmond de Rothschild Investment Partners and OrbiMed with additional new investment from Brace Pharma Capital. As part of the transaction Wellcome Trust converted a Seeding Drug Discovery Award loan to the company into equity. Representatives of Edmond de Rothschild Investment Partners, OrbiMed and the Wellcome Trust will be joining the ReViral Board.
Therapeutic area: Infectious diseases
